To determine the efficacy of nalbuphine in preventing increase in heart rate and mean arterial pressure in response to laryngoscopy and tracheal intubation. Methodology: This double blind randomized controlled trial was conducted on 100 ASA (American Society of Anesthesiologists) grade I-II patients scheduled for general anaesthesia. Patients were randomly allocated to receive either saline (group I, control group, n=50) or nalbuphine 0.2 mg kg-1 (group II, study group, n=50) as a bolus dose 5 minutes before laryngoscopy. Anaesthesia was then induced with propofol (2mg kg-1) and atracurium (0.6mg kg1) and orotracheal intubation was then performed within 30 seconds. Heart rate(HR) and mean arterial pressures(MAP) were recorded before the administration of the study drug, baseline value(T-0), 3 minutes after study drug administration(T-1), immediately after tracheal intubation(T-2) and then after every 1 minute upto 5 minutes (T3-7) and then after 10 minutes of intubation (T-8). Results: The Nalbuphine group showed significantly lesser rise in HR compared to control group after laryngoscopy and orotracheal intubation that continued till 10 minutes after intubation (p-value from ?0.0001-0.0297). The Nalbuphine group also showed significantly lesser rise in MAP compared to control group after laryngoscopy and orotracheal intubation that continued till 5 minutes after intubation (p-value from ?0.0001-0.0152). At 10 minutes post intubation though the rise in MAP was still lesser in Nalbuphine group than control group but it was not significant (p-value=0.0540). Conclusion: Nalbuphine 0.2 mg kg-1 prevents a marked rise in heart rate and mean arterial pressure associated with laryngoscopy and orotracheal intubation.